The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers

International Journal of Clinical Oncology

Volumn 18, Issue 2, 2013, Pages 321-328

  Matsui, Yoshiyuki ^a   Nishiyama, Hiroyuki ^b   Yoshimura, Koji ^a   Xing, Nai Dong ^a   Sumiyoshi, Takayuki ^c   Saito, Ryoichi ^a   Inoue, Takahiro ^a   Kamba, Tomomi ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Gemcitabine; Maintenance chemotherapy; Paclitaxel; Second line chemotherapy; Urothelial cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INTERSTITIAL PNEUMONIA; LIVER METASTASIS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NEURALGIA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84880917836     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0381-0     Document Type: Article

References (23)

1. Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407
2. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564-2569
3. Igawa M, Ohkuchi T, Ueki T et al (1990) Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144:662-665
4. Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448-2458
5. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066-1073
6. Kuroda M, Kotake T, Akaza H et al (1998) Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 28:497-501
7. Sternberg CN (2000) Gemcitabine in bladder cancer. Semin Oncol 27:31-39
8. Roth BJ, Dreicer R, Einhorn LH et al (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270
9. Sternberg CN, Calabro F, Pizzocaro G et al (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92:2993-2998
10. Meluch AA, Greco FA, Burris HA 3rd et al (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19:3018-3024
11. Suyama T, Ueda T, Fukasawa S et al (2009) Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 39:244-250
12. Matsumoto K, Irie A, Satoh T et al (2007) Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol 14:1000-1004 (discussion 1004)
13. Kanai K, Kikuchi E, Ohigashi T et al (2008) Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol 13:510-514
14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
15. Petrioli R, Frediani B, Manganelli A et al (1996) Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77:344-351
16. Dogliotti L, Carteni G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52:134-141
17. Ricci S, Galli L, Chioni A et al (2002) Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 95:1444-1450
18. Dreicer R, Manola J, Schneider DJ et al (2003) Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97:2743-2747
19. Gitlitz BJ, Baker C, Chapman Y et al (2003) A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98:1863-1869
20. Takahashi T, Higashi S, Nishiyama H et al (2006) Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol 36:104-108
21. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
22. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608
23. Committee for Establishment of the Clinical Practice Guidelines for the Management of Bladder Cancer and the Japanese Urological Association (2009) Evidence-based clinical practice guidelines for bladder cancer. Igaku Tosho Shuppan, Tokyo